The US Food and Drug Administration (FDA) has issued a warning about the serious risk of an allergic reaction called anaphylaxis when using Copaxone, a medication used to treat multiple sclerosis. Produced by Teva Pharmaceutical Industries,Copaxone was once among the top-selling drugs in the U.S., generating over $1.3 billion annually before losing patent exclusivity. The FDA notes that anaphylaxis can occur at any time after any dose of Copaxone or even months or years after starting treatment. Most patients experience symptoms within one hour of injection, highlighting the urgency for healthcare providers to remain vigilant.
Please register now for free access and gain exclusive features and insights into the pharmaceutical and biotech industries. If you’re already registered, log in to continue reading. For a limited time, consider a trial subscription starting at $77 per month to explore our comprehensive updates on industry performance and products.
Source: https://www.thepharmaletter.com/fda-warns-of-rare-but-serious-allergic-reaction-with-glatiramer